• Hamad Dheir, Savaş Sipahi, Selçuk Yaylacı, Esma Seda Çetin, Ahmed Bilal Genç, Necattin Fırat, Mehmet Köroğlu, Gürkan Muratdağı, Yakup Tomak, Kezban Özmen, Ömer Faruk Ateş, and Oğuz Karabay.
• Division of Nephrology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
• Turk J Med Sci. 2021 Apr 30; 51 (2): 428434428-434.

Background/AimWe aimed to identify clinical settings of renal transplant patients with COVID-19.Materials And MethodsIn this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1st, 2020. Characteristics of the patients, including basal and last outpatient biochemical parameters were recorded. Discontinuation or dosage reduction of immunosuppressives and other treatment information was documented.ResultsTwenty patients were included in this study, of whom 18 were discharged and 2 died in hospital. The mean duration of hospitalization and follow-up were 9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Fourteen patients (70%) were male and mean age was 48.0 ± 10.3 years. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/ day (50%) or dexamethasone (50%). Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued. Hemodialysis was needed for 10% of patients. Acute kidney injury was detected in 25% of the patients. With respect to hospitalization time and complications, there was no significant difference between patients who used dexamethasone and those who did not (P > 0.05). The discontinued immunosuppressives were resumed within 2 to 4 weeks after discharge according to the severity of disease. No rehospitalization or acute rejection was detected during the follow-up of the patients.ConclusionRenal transplant patients are considered a high risk group for COVID-19. It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients.This work is licensed under a Creative Commons Attribution 4.0 International License.

49 keywords...

hide…